Eli Lilly: promising trial for tirzepatide injection

(CercleFinance.com) - Eli Lilly has announced positive results from a Phase III study evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg) in adults with heart failure with preserved ejection fraction (HFpEF) and obesity.


Tirzepatide showed 'significant' improvements in heart failure outcomes and symptoms, compared with placebo, the laboratory points out.

All secondary endpoints, including exercise capacity, reduced inflammation and weight loss, were also met.

Fizepatide reduced body weight by 15.7% versus 2.2% for placebo, adds Eli Lilly.

Jeff Emmick, Vice President at Eli Lilly, described the trial as "unprecedented" and stressed the importance of these results for a population with previously limited treatment options.


Copyright (c) 2024 CercleFinance.com. All rights reserved.